Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 7

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 $2,095 

    Supplemental
    disclosure of cash flow information: 

    Share
    subscription receivable 
    $1,100,000  
    $— 
  
    Offering
    costs included in equity 
    $848,201  
    $— 
  
    Offering
    costs included in accrued offering costs 
    $94,516  
    $31,583 
  
    Deferred
    offering costs paid through promissory note – related party 
    $204,000  
    $29,500 
  
    Accretion
    and remeasurement of redeemable ordinary shares to redemption value 
    $19,779,326  
    $— 
  
    Deferred
    underwriting fee payable 
    $6,900,000  
    $— 
  
    Offering
    costs paid via prepaid expense 
    $3,640  
     — 

The
accompanying notes are an integral part of the unaudited financial statements.

4

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

NOTE
1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Drugs
Made In America Acquisition Corp. (the “Company”) is a blank check company newly incorporated in the Cayman Islands on May 23,
2024. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or other similar business combination with one or more businesses (the “Business Combination”).

Although
the Company may acquire a business in any industry, it intends to focus on companies in the pharmaceutical industry. The Company is an
early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging
growth companies.

As
of September 30, 2025, the Company had not commenced any operations. All activity for the period from May 23, 2024 (inception) through
September 30, 2025 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which
is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company
will not generate any operating revenues until after the completion of its initial Business Combination